ATE236258T1 - Gelonin und einen antikörper entahltende immuntoxine - Google Patents

Gelonin und einen antikörper entahltende immuntoxine

Info

Publication number
ATE236258T1
ATE236258T1 AT94917380T AT94917380T ATE236258T1 AT E236258 T1 ATE236258 T1 AT E236258T1 AT 94917380 T AT94917380 T AT 94917380T AT 94917380 T AT94917380 T AT 94917380T AT E236258 T1 ATE236258 T1 AT E236258T1
Authority
AT
Austria
Prior art keywords
rips
vectors
analogs
therapeutic agents
rip
Prior art date
Application number
AT94917380T
Other languages
English (en)
Inventor
Marc D Better
Stephen F Carroll
Gary M Studnicka
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Application granted granted Critical
Publication of ATE236258T1 publication Critical patent/ATE236258T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT94917380T 1993-05-12 1994-05-12 Gelonin und einen antikörper entahltende immuntoxine ATE236258T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6469193A 1993-05-12 1993-05-12
PCT/US1994/005348 WO1994026910A1 (en) 1993-05-12 1994-05-12 Immunotoxins comprising gelonin and an antibody

Publications (1)

Publication Number Publication Date
ATE236258T1 true ATE236258T1 (de) 2003-04-15

Family

ID=22057667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94917380T ATE236258T1 (de) 1993-05-12 1994-05-12 Gelonin und einen antikörper entahltende immuntoxine

Country Status (7)

Country Link
EP (1) EP0700444B1 (de)
JP (1) JPH08510642A (de)
AT (1) ATE236258T1 (de)
AU (1) AU6912294A (de)
CA (1) CA2162689C (de)
DE (1) DE69432412T2 (de)
WO (1) WO1994026910A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
WO1998055623A1 (en) 1997-06-06 1998-12-10 Tanox Pharma B.V. Type-1 ribosome-inactivating protein
WO1998058678A1 (en) * 1997-06-20 1998-12-30 Tanox Pharma B.V. Anti-cd40l immunotoxins for the treatment of diseases
CA2391925A1 (en) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Antibodies
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
WO2007045465A1 (en) 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2864361A4 (de) * 2012-06-26 2016-06-01 Biovalence Sdn Bhd Dosierungsschema für fusionsverbindungen
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
EP2970487B1 (de) 2013-03-12 2020-03-11 Molecular Templates, Inc. Zytotoxische proteine mit zellgerichteten bindungsregionen und shigatoxin-a-untereinheitsregionen zur selektiven tötung von spezifischen zellarten
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
KR20160113158A (ko) 2014-01-27 2016-09-28 몰레큘러 템플레이츠, 인코퍼레이션. 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
US10815469B2 (en) 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
JP6444486B2 (ja) 2015-02-05 2018-12-26 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 志賀毒素aサブユニットエフェクター領域を含む多価cd20結合分子及びそれらの強化組成物
JP6771492B2 (ja) 2015-05-30 2020-10-21 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 脱免疫化された志賀毒素aサブユニット足場及びそれを含む細胞標的化分子
JP7075134B2 (ja) 2016-12-07 2022-05-25 モレキュラー テンプレーツ,インク. 部位特異的コンジュゲーションのための志賀毒素aサブユニットエフェクターポリペプチド、志賀毒素エフェクター足場、及び細胞標的化分子
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2062582C (en) * 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
CA2110799A1 (en) * 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
CA2115049C (en) * 1991-09-06 2003-10-21 Michael G. Rosenblum Dna sequences encoding gelonin polypeptide
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins

Also Published As

Publication number Publication date
DE69432412D1 (de) 2003-05-08
CA2162689A1 (en) 1994-11-24
EP0700444B1 (de) 2003-04-02
EP0700444A1 (de) 1996-03-13
CA2162689C (en) 2000-07-18
AU6912294A (en) 1994-12-12
DE69432412T2 (de) 2004-01-29
WO1994026910A1 (en) 1994-11-24
JPH08510642A (ja) 1996-11-12

Similar Documents

Publication Publication Date Title
ATE236258T1 (de) Gelonin und einen antikörper entahltende immuntoxine
DE69233045D1 (de) Ribosomen inaktivierende proteine enthaltende materialien, verfahren zu ihrer herstellung und ihre verwendung
IL150571A0 (en) Novel chimeric proteins and methods for using the same
Jensen et al. Primary structure of human alpha 2-macroglobulin. Complete disulfide bridge assignment and localization of two interchain bridges in the dimeric proteinase binding unit.
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
DE68926971D1 (de) Klonierte gene, die für elam-1 und für dessen fusionsproteine kodieren sowie die exprimierten proteinprodukte, pharmazeutische zusammensetzungen und deren verwendung
MX9301700A (es) Muteinas del factor de necrosis tumoral humano, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
YU127390A (sh) Nova antitela reaktivna sa humanim karcinomima
ATE245697T1 (de) Klonierung und expression eines gens, das bryodin 1 aus bryonia dioica kodiert
DE60032486D1 (de) Prion protein peptide und deren verwendung
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
DE69637148D1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
EA200000144A1 (ru) Направленный цитолиз клеток-мишеней, агенты и композиции, вызывающие цитолиз, и соединения, которые можно использовать для получения этих агентов
EP1262548A4 (de) Apoptose-induzierendes polypeptid
MXPA02008239A (es) Gen humano de la esquizofrenia.
CN1056084C (zh) 抗与表面抗原相关的cd33的免疫毒素
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO1999054463A3 (en) Human k+ ion channel and therapeutic applications thereof
EP0815240A4 (de) Neue menschliche proteine, die cyclinebhängigen kinasen ähneln, sowie methoden zu deren verwendung
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
Bernhard et al. Materials comprising and methods of preparation and use for ribosome-inactivating proteins
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
WO2001029068A3 (en) A eag gene encoding for a potassium channel
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
DK0811068T3 (da) Humane DNase I varianter

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties